https://www.biospace.com/business/bms-adds-2b-to-cost-cutting-plans-eyes-deals-after-cobenfy-success
Bristol Myer Squibb on the hunt.
The company is also on the lookout for deals or partnerships to further build out the pipeline.
“We’re really focused on strengthening our position in the core therapeutic areas that we have today,” Boerner said. “We need to like the science and feel that we’re the rightful owners of it. The financials have to make sense.”
Add to My Watchlist
What is My Watchlist?
